p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape

BACKGROUND p300 impacts the transcription of several genes involved in key pathways critical to PCa progression. Therefore, we evaluated the prognostic value of p300 expression and its correlation with nuclear alterations seen in tumor cells in men with long‐term follow‐up after radical prostatectom...

Full description

Saved in:
Bibliographic Details
Published inThe Prostate Vol. 68; no. 10; pp. 1097 - 1104
Main Authors Isharwal, Sumit, Miller, Michael C., Marlow, Cameron, Makarov, Danil V., Partin, Alan W., Veltri, Robert W.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.07.2008
Wiley-Liss
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:BACKGROUND p300 impacts the transcription of several genes involved in key pathways critical to PCa progression. Therefore, we evaluated the prognostic value of p300 expression and its correlation with nuclear alterations seen in tumor cells in men with long‐term follow‐up after radical prostatectomy (RP). METHODS NCI Cooperative Prostate Cancer Tissue Resource tissue microarray cores of 92 RP cases (56 non‐recurrences and 36 PSA recurrences) were utilized for the study. p300 expression was assessed by quantitative immunohistochemistry and nuclear alterations in Feulgen‐stained nuclei were evaluated by digital image analysis using the AutoCyte™ Pathology Workstation. Cox proportional hazards regression, Spearman's rank correlation, and Kaplan–Meier plots were employed to analyze the data. RESULTS p300 expression significantly correlated with nuclear alterations seen in tumor cells; specifically with circular form factor (P = 0.012) and minimum feret (P = 0.048). p300 expression in high grade tumors (Gleason score ≥7) was significantly higher compared to low grade tumors (Gleason score <7) [17.7% versus 13.7%, respectively, P = 0.03]. TNM stage, Gleason score, and p300 expression were univariately significant in the prediction of PCa biochemical recurrence‐free survival (P ≤ 0.05). p300 expression remained significant in the multivariate model (P = 0.03) while Gleason score showed a trend toward significance (P = 0.06). Patients with a Gleason score ≥7 and p300 expression >24% showed the highest risk for PCa biochemical recurrence (P = 0.002). CONCLUSIONS p300 expression correlates with nuclear alterations seen in tumor cells and has prognostic value in predicting long‐term PCa biochemical recurrence‐free survival. Prostate 68:1097–1104, 2008. © 2008 Wiley‐Liss, Inc.
Bibliography:ark:/67375/WNG-G0ZQLT4D-1
istex:320CCDAA14F12AB94630AB9899FC1146BD2C94E8
ArticleID:PROS20772
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
M. Craig Miller, B.S., 8032 Covered Bridge Road, Quakertown, PA, (215) 529-5578, aggie90@comcast.net
Cameron Marlow, B.S., Johns Hopkins University School of Medicine, Department of Urology, 600 North Wolfe Street, Baltimore, MD 21287, (410) 955-4494, (410) 614-3695 (Fax), cmarlow2@jhmi.edu
Alan W. Partin, M.D., Ph.D., Johns Hopkins University SOM, Department of Urology, 600 North Wolfe Street, Baltimore, MD 21287, (410) 614-4876, (410) 614-8096 (Fax), apartin@jhmi.edu
Sumit Isharwal, M.D., Post-Doctoral Fellow, Department of Urology, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, (410) 955-4494, (410) 614-3695 (Fax), sisharw1@jhmi.edu
Danil V. Makarov, M.D., Johns Hopkins University SOM, Department of Urology, 600 North Wolfe Street, Baltimore, MD 21287, (410) 955-4494, (410) 955-0833 (Fax), dmakarov@jhmi.edu
ISSN:0270-4137
1097-0045
DOI:10.1002/pros.20772